Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR
Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy
Leukemia, Myeloid, Acute
BIOLOGICAL: Human Stem Cell Transplantation|DRUG: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
Percent of Patients alive after 4 years (Overall Survival), The status of each patient alive/not alive is surveyed every 3 months in year 1+2 and every 6 months in year 3+4 after randomisation., 4 years
Disease-free survival, 4 years|Cumulative incidence of relapse, 4 years|Cumulative incidence of non-relapse mortality, 4 years|Quality of life assessed by questionnaires, Scores assessed by validated questionnaires (8 subscales: physical function, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health), 4 years
Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy